HIF-1 as a target for drug development
The DOI matches its Crossref record; 116 of the 116 references it cites were found in a registry or an index.
Abstract
Sensing and responding to fluxes in oxygen tension is perhaps the single most important variable in physiology, and animal tissues have developed a number of essential mechanisms to cope with the stress of low physiological oxygen levels, or hypoxia. Among these coping mechanisms is the response mediated by the hypoxia-inducible transcription factor, or HIF-1. HIF-1 is an essential component in changing the transcriptional repertoire of tissues as oxygen levels drop, and could prove to be a very important target for drug development, as treatments evolve for diseases, such as cancer, heart disease and stroke, in which hypoxia is a central aspect.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Furthermore, growing evidence showed that the strong cell–cell contacts of tumor spheroids in combination with dense ECM deposition is responsible for chemoresistance by posing a physical barrier to the penetration of chemotherapeutics and immune cells similar to in vivo.[ 48 ]”
From 3D Biomimetic Models to Reconstitute Tumor Microenvironment In Vitro: Spheroids, Organoids, and Tumor‐on‐a‐Chip (2023) · cites this paper as [48]
Citations
Cites
Jaakkola, P., Mole, D. R., Tian, Y.-M., Wilson, M. I., Gielbert, J., Gaskell, S. J., Kriegsheim, A. V., Hebestreit, H. F., Mukherji, M., Schofield, C. J., et al. (2001) · Science · doi:10.1126/science.1059796 · Cited by 5,535
The tumour suppressor protein VHL targets hypoxia-inducible factors for oxygen-dependent proteolysis
Maxwell, P. H., Wiesener, M. S., Chang, G.-W., Clifford, S. C., Vaux, E. C., Cockman, M. E., Wykoff, C. C., Pugh, C. W., Maher, E. R., & Ratcliffe, P. J. (1999) · Nature · doi:10.1038/20459 · Cited by 5,180
Hypoxia — a key regulatory factor in tumour growth
Harris, A. L. (2002) · Nature Reviews Cancer · doi:10.1038/nrc704 · Cited by 5,177 · cited 1×
“Most importantly, overexpression of HIF-1α or HIF-2α have been implicated as poor prognostic indicators for a variety of tumour”
BackgroundHIFα Targeted for VHL-Mediated Destruction by Proline Hydroxylation: Implications for O 2 Sensing
Ivan, M., Kondo, K., Yang, H., Kim, W., Valiando, J., Ohh, M., Salic, A., Asara, J. M., Lane, W. S., & Kaelin Jr., W. G. (2001) · Science · doi:10.1126/science.1059817 · Cited by 4,735
Vascular endothelial growth factor induced by hypoxia may mediate hypoxia-initiated angiogenesis
Shweiki, D., Itin, A., Soffer, D., & Keshet, E. (1992) · Nature · doi:10.1038/359843a0 · Cited by 4,617
Epstein, A. C. R., Gleadle, J. M., McNeill, L. A., Hewitson, K. S., O'Rourke, J., Mole, D. R., Mukherji, M., Metzen, E., Wilson, M. I., Dhanda, A., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00507-4 · Cited by 3,333
A conserved family of prolyl-4-hydroxylases that modify HIF
Bruick, R. K., & McKnight, S. L. (2001) · Science · doi:10.1126/science.1066373 · Cited by 2,549
Role of HIF-1α in hypoxia-mediated apoptosis, cell proliferation and tumour angiogenesis
Carmeliet, P., Dor, Y., Herbert, J.-M., Fukumura, D., Brusselmans, K., Dewerchin, M., Neeman, M., Bono, F., Abramovitch, R., Maxwell, P., et al. (1998) · Nature · doi:10.1038/28867 · Cited by 2,502
Cellular and developmental control of O 2 homeostasis by hypoxia-inducible factor 1α
Iyer, N. V., Kotch, L. E., Agani, F., Leung, S. W., Laughner, E., Wenger, R. H., Gassmann, M., Gearhart, J. D., Lawler, A. M., Yu, A. Y., et al. (1998) · Genes & Development · doi:10.1101/gad.12.2.149 · Cited by 2,476 · cited 1×
“Although the role of HIF-1α in human tumours remains correlative, in transplanted tumours in immunodeficient mice, loss of HIF-1α or HIF-1β results in reduced tumour growth, decreased angiogenesis and increased responsiveness to radiotherap”
BackgroundHuang, L. E., Gu, J., Schau, M., & Bunn, H. F. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.14.7987 · Cited by 2,113
Research works printed but not linked: 1
- Flamme, I., Frolich, T. & Risau, W. Molecular mechanisms of vasculogenesis and embryonic angiogenesis. J. Cell. Physiol. 173, 206–210 (1997). · DOI · Paper page
Cited by
Targeting hypoxia in cancer therapy
Wilson, W. R., & Hay, M. P. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3064 · Cited by 3,172
“Multiple components of the HIF1 signalling pathway have been identified as candidate drug target”
BackgroundModes of resistance to anti-angiogenic therapy
Bergers, G., & Hanahan, D. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2442 · Cited by 2,953
“The HIF regulatory network also holds promise as a target, given its global effects on angiogenesis, invasion and stress-adaptive cell physiolog”
BackgroundExploiting tumour hypoxia in cancer treatment
Brown, J. M., & Wilson, W. R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1367 · Cited by 2,828
“Targeting HIF-1 The characteristics, functions and possibilities for targeting HIF-1 in cancer therapy have been recently reviewe”
BackgroundHypoxia, HIF1 and glucose metabolism in the solid tumour
Denko, N. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2468 · Cited by 1,707
“HIF1 inhibitors with metabolic effects Investigators are also attempting to inhibit the HIF1 transcription factor in an effort to block the metabolic effects as well as other physiological pathways that are regulated by HIF1 in the solid tumour (such as angiogenesis”
BackgroundHypoxic microenvironment in cancer: molecular mechanisms and therapeutic interventions
Chen, Z., Han, F., Du, Y., Shi, H., & Zhou, W. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01332-8 · Cited by 1,612
“HIF-1α is an oxygen-unstable protein that becomes stable in response to hypoxia, iron chelators, and divalent cations.(81,82) In cell culture under hypoxic conditions, HIF-1α mRNA levels did not change, but HIF-1α protein levels increased.”
BackgroundThe impact of O2 availability on human cancer
Bertout, J. A., Patel, S. A., & Simon, M. C. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2540 · Cited by 1,365
“The role of HIFs in cancer On the basis of the analysis of human cancer biopsy samples and experimental animal models, it has become increasingly clear that HIFs have a crucial role in cancer progressio”
BackgroundImpact of Natural Products on Developing New Anti-Cancer Agents
Cragg, G. M., Grothaus, P. G., & Newman, D. J. (2009) · Chemical Reviews · doi:10.1021/cr900019j · Cited by 1,302
HIF transcription factors, inflammation, and immunity
Palazon, A., Goldrath, A. W., Nizet, V., & Johnson, R. S. (2014) · Immunity · doi:10.1016/j.immuni.2014.09.008 · Cited by 1,195
“In this regard, HIF-1a inhibition could be a potential strategy for limiting exacerbated responses, such as arthritis (Giaccia et al., 2003).”
BackgroundSelf-citationTranscriptional regulation of vascular endothelial cell responses to hypoxia by HIF-1
Manalo, D. J., Rowan, A., Lavoie, T., Natarajan, L., Kelly, B. D., Ye, S. Q., Garcia, J. G. N., & Semenza, G. L. (2005) · Blood · doi:10.1182/blood-2004-07-2958 · Cited by 1,154
Hypoxia, DNA repair and genetic instability
Bristow, R. G., & Hill, R. P. (2008) · Nature Reviews Cancer · doi:10.1038/nrc2344 · Cited by 1,140
Hydroxylation of HIF-1: Oxygen Sensing at the Molecular Level
Semenza, G. L. (2004) · Physiology · doi:10.1152/physiol.00001.2004 · Cited by 905
Role of tumor-associated macrophages in tumor progression and invasion
Mantovani, A., Schioppa, T., Porta, C., Allavena, P., & Sica, A. (2006) · Cancer and Metastasis Reviews · doi:10.1007/s10555-006-9001-7 · Cited by 888
“Similarly to NF-κB, inhibition of HIF-1α is considered a promising therapeutic approach against cancer [48] and in fact some of its inhibitors (e.”
BackgroundProgress and Promise of FDG-PET Imaging for Cancer Patient Management and Oncologic Drug Development
Kelloff, G. J., Hoffman, J. M., Johnson, B., Scher, H. I., Siegel, B. A., Cheng, E. Y., Cheson, B. D., O'Shaughnessy, J., Guyton, K. Z., Mankoff, D. A., et al. (2005) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-04-2626 · Cited by 671
Radiation oncology: a century of achievements
Bernier, J., Hall, E. J., & Giaccia, A. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1451 · Cited by 628
“fcgi?db=gene&cmd=Retrieve&dopt=Graphics&list_uids=3091,405">HIF1 ) transcription facto”
Self-citationKim, J.-W., Gao, P., Liu, Y.-C., Semenza, G. L., & Dang, C. V. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.00440-07 · Cited by 658
Cancer related inflammation: the macrophage connection
Sica, A., Allavena, P., & Mantovani, A. (2008) · Cancer Letters · doi:10.1016/j.canlet.2008.03.028 · Cited by 601
“[73] A.”
BackgroundInfluentialOxidation in rheumatoid arthritis.
Hitchon, C. A., & El-Gabalawy, H. S. (2004) · Arthritis Research · doi:10.1186/ar1447 · Cited by 667
“The central role of HIF-1α in mediating hypoxic responses has suggested new therapeutic opportunities, particularly in cancer and cardiovascular medicine [ 130 ,131].”
BackgroundJunD Reduces Tumor Angiogenesis by Protecting Cells from Oxidative Stress
Gerald, D., Berra, E., Frapart, Y. M., Chan, D. A., Giaccia, A. J., Mansuy, D., Pouysségur, J., Yaniv, M., & Mechta-Grigoriou, F. (2004) · Cell · doi:10.1016/j.cell.2004.08.025 · Cited by 588
Self-citationHIF-Dependent Antitumorigenic Effect of Antioxidants In Vivo
Gao, P., Zhang, H., Dinavahi, R., Li, F., Xiang, Y., Raman, V., Bhujwalla, Z. M., Felsher, D. W., Cheng, L., Pevsner, J., et al. (2007) · Cancer Cell · doi:10.1016/j.ccr.2007.08.004 · Cited by 523
Echinomycin, a small-molecule inhibitor of hypoxia-inducible factor-1 DNA-binding activity.
Kong, D., Park, E. J., Stephen, A. G., Calvani, M., Cardellina, J. H., Monks, A., Fisher, R. J., Shoemaker, R. H., & Melillo, G. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-1235 · Cited by 508
“Therefore, HIF-1 is an attractive target for cancer therapy (5, 24, 25).”
BackgroundA history of exploring cancer in context
Maman, S., & Witz, I. P. (2018) · Nature Reviews Cancer · doi:10.1038/s41568-018-0006-7 · Cited by 502
Hypoxia signaling in human health and diseases: implications and prospects for therapeutics
Luo, Z., Tian, M., Yang, G., Tan, Q., Chen, Y., Li, G., Zhang, Q., Li, Y., Wan, P., & Wu, J. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01080-1 · Cited by 499
Mechanisms of the Anti-Cancer and Anti-Inflammatory Actions of Vitamin D
Krishnan, A. V., & Feldman, D. (2011) · Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-010510-100611 · Cited by 470
“Calcitriol inhibits VEGF-induced endothelial cell tube formation in vitro and decreases tumor vascularization in mice that bear xenografts of BCa cells overexpressing VEGF (157).”
BackgroundInfluentialHypoxic gene expression and metastasis
Le, Q.-T., Denko, N. C., & Giaccia, A. J. (2004) · Cancer and Metastasis Reviews · doi:10.1023/b:canc.0000031768.89246.d7 · Cited by 468
“Recent studies have shown an intricate system of hypoxic regulation of HIF-1a activity in the cells that involves prolyl hydroxylases, asparagine hydroxylases (FIH – factor inhibiting HIF-1), Von Hippel Lindau (VHL) protein-based E3 ubiquitin ligase complexes, redox factor-1 (REF-1) and thioredoxin [18,19].”
BackgroundSelf-citationSmith, K., Gunaratnam, L., Morley, M., Franovic, A., Mekhail, K., & Lee, S. (2005) · Cancer Research · doi:10.1158/0008-5472.can-05-0169 · Cited by 458
Regulation of HIF-1α Stability through S-Nitrosylation
Li, F., Sonveaux, P., Rabbani, Z. N., Liu, S., Yan, B., Huang, Q., Vujaskovic, Z., Dewhirst, M. W., & Li, C.-Y. (2007) · Molecular Cell · doi:10.1016/j.molcel.2007.02.024 · Cited by 437
“A significant amount of effort is now being devoted to the development of HIF-1 inhibitors as anti-cancer drugs(Giaccia et al., 2003; Rapisarda et al., 2002; Sutphin et al., 2004).”
Eckle, T., Köhler, D., Lehmann, R., El Kasmi, K. C., & Eltzschig, H. K. (2008) · Circulation · doi:10.1161/circulationaha.107.758516 · Cited by 409
Regulation of Osteogenesis-Angiogenesis Coupling by HIFs and VEGF
Schipani, E., Maes, C., Carmeliet, G., & Semenza, G. L. (2009) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.090602 · Cited by 406
“cancers contain regions of severe hypoxia, resulting in high levels of HIF-1a that drive tumor progression,((32,35)) and inhibition of HIF-1a has been proposed as a potentially powerful approach.”
BackgroundZagzag, D., Lukyanov, Y., Lan, L., Ali, M. A., Esencay, M., Mendez, O., Yee, H., Voura, E. B., & Newcomb, E. W. (2006) · Laboratory Investigation · doi:10.1038/labinvest.3700482 · Cited by 396
Lin, Q., Li, S., Jiang, N., Jin, H., Shao, X., Zhu, X., Wu, J., Zhang, M., Zhang, Z., Shen, J., et al. (2021) · Autophagy · doi:10.1080/15548627.2020.1848971 · Cited by 391
“In contrast, HIF1A is stable under hypoxic conditions [31].”
BackgroundMolecular Biology of Erythropoietin
JELKMANN, W. (2004) · Internal Medicine · doi:10.2169/internalmedicine.43.649 · Cited by 383
Tumor Hypoxia in Cancer Therapy
Brown, J. M. (2007) · Methods in Enzymology · doi:10.1016/s0076-6879(07)35015-5 · Cited by 359
Pleiotropic effects of HIF-1 blockade on tumor radiosensitivity
Moeller, B. J., Dreher, M. R., Rabbani, Z. N., Schroeder, T., Cao, Y., Li, C. Y., & Dewhirst, M. W. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.06.016 · Cited by 374
“The idea that HIF-1 may be a good target for cancer therapy is not a new one (Giaccia et al., 2003; Semenza, 2003).”
BackgroundBioengineered and biohybrid bacteria-based systems for drug delivery
Hosseinidoust, Z., Mostaghaci, B., Yasa, O., Park, B.-W., Singh, A. V., & Sitti, M. (2016) · Advanced Drug Delivery Reviews · doi:10.1016/j.addr.2016.09.007 · Cited by 368
Human high-altitude adaptation: forward genetics meets the HIF pathway
Bigham, A. W., & Lee, F. S. (2014) · Genes & Development · doi:10.1101/gad.250167.114 · Cited by 349
“HIF is the master transcriptional regulator of the hypoxic response in metazoans (Semenza 1999; Giaccia et al. 2003; Wenger et al. 2005; Lendahl et al. 2009).”
BackgroundCarroll, V. A., & Ashcroft, M. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-2519 · Cited by 352
Cell death in pancreatic cancer: from pathogenesis to therapy
Chen, X., Zeh, H. J., Kang, R., Kroemer, G., & Tang, D. (2021) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-021-00486-6 · Cited by 336
HIF-1α Induces Genetic Instability by Transcriptionally Downregulating MutSα Expression
Koshiji, M., To, K. K.-W., Hammer, S., Kumamoto, K., Harris, A. L., Modrich, P., & Huang, L. E. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.02.015 · Cited by 346
The many faces of the adamantyl group in drug design
Liu, J., Obando, D., Liao, V., Lifa, T., & Codd, R. (2011) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2011.01.047 · Cited by 309
Hypoxia-driven pathways in bone development, regeneration and disease
Maes, C., Carmeliet, G., & Schipani, E. (2012) · Nature Reviews Rheumatology · doi:10.1038/nrrheum.2012.36 · Cited by 300
Erythropoietin and the hypoxic brain
Marti, H. H. (2004) · Journal of Experimental Biology · doi:10.1242/jeb.01049 · Cited by 303
Estrada, J. C., Albo, C., Benguría, A., Dopazo, A., López-Romero, P., Carrera-Quintanar, L., Roche, E., Clemente, E. P., Enríquez, J. A., Bernad, A., et al. (2012) · Cell Death & Differentiation · doi:10.1038/cdd.2011.172 · Cited by 297
“One of the best-characterized mechanisms of glycolysis upregulation is the hypoxia response through activation of HIF-1.”
BackgroundNegative and positive regulation of HIF-1: A complex network
Bárdos, J. I., & Ashcroft, M. (2005) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2005.05.001 · Cited by 285
Recent advances in hypoxia-inducible factor (HIF)-1 inhibitors
Xia, Y., Choi, H.-K., & Lee, K. (2012) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2012.01.033 · Cited by 278
Meng, L., Cheng, Y., Tong, X., Gan, S., Ding, Y., Zhang, Y., Wang, C., Xu, L., Zhu, Y., Wu, J., et al. (2018) · ACS Nano · doi:10.1021/acsnano.8b03590 · Cited by 268
Development of HIF‐1 inhibitors for cancer therapy
Onnis, B., Rapisarda, A., & Melillo, G. (2009) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2009.00876.x · Cited by 268
Targeting Protein–Protein Interactions for Therapeutic Intervention: A Challenge for the Future
Zinzalla, G., & Thurston, D. E. (2009) · Future Medicinal Chemistry · doi:10.4155/fmc.09.12 · Cited by 260
Cellular and molecular pathways linking inflammation and cancer
Porta, C., Larghi, P., Rimoldi, M., Grazia Totaro, M., Allavena, P., Mantovani, A., & Sica, A. (2009) · Immunobiology · doi:10.1016/j.imbio.2009.06.014 · Cited by 250
“2009) as well as a potential target for anticancer therapies (Giaccia et al. 2003).”
Review: Hypoxia-Inducible Factor-1 (HIF-1): A Novel Transcription Factor in Immune Reactions
Hellwig-Bürgel, T., Stiehl, D. P., Wagner, A. E., Metzen, E., & Jelkmann, W. (2005) · Journal of Interferon & Cytokine Research · doi:10.1089/jir.2005.25.297 · Cited by 254
Zhang, W., Shi, X., Peng, Y., Wu, M., Zhang, P., Xie, R., Wu, Y., Yan, Q., Liu, S., & Wang, J. (2015) · PLOS ONE · doi:10.1371/journal.pone.0129603 · Cited by 261
Kong, X., Lin, Z., Liang, D., Fath, D., Sang, N., & Caro, J. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.26.6.2019-2028.2006 · Cited by 258
“The transcriptional complex hypoxia-inducible factor 1 (HIF-1) plays a key role in the cellular adaptations to the lack or deficiency of oxygen supply (17).”
BackgroundA Molecule Targeting VHL-Deficient Renal Cell Carcinoma that Induces Autophagy
Turcotte, S., Chan, D. A., Sutphin, P. D., Hay, M. P., Denny, W. A., & Giaccia, A. J. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.06.004 · Cited by 251
“To develop new compounds with higher therapeutic indices, targeted genetic approaches should be considered (Giaccia et al., 2003; Sutphin et al., 2004).”
Self-citationZhao, X., Li, F., Li, Y., Wang, H., Ren, H., Chen, J., Nie, G., & Hao, J. (2015) · Biomaterials · doi:10.1016/j.biomaterials.2014.12.028 · Cited by 247
Noman, M. Z., Janji, B., Kaminska, B., Van Moer, K., Pierson, S., Przanowski, P., Buart, S., Berchem, G., Romero, P., Mami-Chouaib, F., et al. (2011) · Cancer Research · doi:10.1158/0008-5472.can-11-1094 · Cited by 256
“favors the emergence of tumor phenotypes that are resistant to therapy approaches (10).”
Nanoparticles for modulating tumor microenvironment to improve drug delivery and tumor therapy
Yang, S., & Gao, H. (2017) · Pharmacological Research · doi:10.1016/j.phrs.2017.05.004 · Cited by 256
Sun, Y., Zhao, D., Wang, G., Wang, Y., Cao, L., Sun, J., Jiang, Q., & He, Z. (2020) · Acta Pharmaceutica Sinica B · doi:10.1016/j.apsb.2020.01.004 · Cited by 250
Inhibition of hypoxia-inducible factor is sufficient for growth suppression of VHL−/− tumors
Zimmer, M., Doucette, D., Siddiqui, N., & Iliopoulos, O. (2004) · Molecular Cancer Research · doi:10.1158/1541-7786.89.2.2 · Cited by 244
“In addition, the discovery and application of highly specific HIF inhibitors in vivo will complement the evaluation of HIF as molecular target for drug development (38).”
BackgroundAntiangiogenic therapy and tumor progression
Blagosklonny, M. V. (2004) · Cancer Cell · doi:10.1016/s1535-6108(03)00336-2 · Cited by 235
Selective Inhibition of Hypoxia-Inducible Factor 1α Ameliorates Adipose Tissue Dysfunction
Sun, K., Halberg, N., Khan, M., Magalang, U. J., & Scherer, P. E. (2013) · Molecular and Cellular Biology · doi:10.1128/mcb.00951-12 · Cited by 231
“Surprisingly, there are no reports in the literature that focus on targeted therapies in this area despite widespread efforts in the context of cancer (21, 22, 51).”
BackgroundTargeting hypoxia cell signaling for cancer therapy
Melillo, G. (2007) · Cancer and Metastasis Reviews · doi:10.1007/s10555-007-9059-x · Cited by 230
Choi, H., Chun, Y.-S., Kim, S.-W., Kim, M.-S., & Park, J.-W. (2006) · Molecular Pharmacology · doi:10.1124/mol.106.025817 · Cited by 219
“alone, and as a result, several HIF-1 inhibitors are being developed for cancer chemotherapy (Giaccia et al., 2003; Yeo et al., 2004).”
BackgroundSignalling via the hypoxia-inducible factor-1α requires multiple posttranslational modifications
Brahimi-Horn, C., Mazure, N., & Pouysségur, J. (2005) · Cellular Signalling · doi:10.1016/j.cellsig.2004.04.010 · Cited by 214
Baek, J. H., Mahon, P. C., Oh, J., Kelly, B., Krishnamachary, B., Pearson, M., Chan, D. A., Giaccia, A. J., & Semenza, G. L. (2005) · Molecular Cell · doi:10.1016/j.molcel.2005.01.011 · Cited by 222
Self-citationLluis, J. M., Buricchi, F., Chiarugi, P., Morales, A., & Fernandez-Checa, J. C. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0515 · Cited by 221
“Given the key role of HIF-1a stabilization and NF-nB activation in promoting survival of cancer cells, angiogenesis, neovascularization, glycolytic ATP generation, and tumor invasion (1, 2, 10), and Figure 5.”
BackgroundThe role of tumor-associated macrophages in breast cancer progression
OBEID, E., NANDA, R., FU, Y.-X., & OLOPADE, O. I. (2013) · International Journal of Oncology · doi:10.3892/ijo.2013.1938 · Cited by 204
“increased patient mortality in some cancers (29).”
Hif-1α regulates differentiation of limb bud mesenchyme and joint development
Provot, S., Zinyk, D., Gunes, Y., Kathri, R., Le, Q., Kronenberg, H. M., Johnson, R. S., Longaker, M. T., Giaccia, A. J., & Schipani, E. (2007) · The Journal of Cell Biology · doi:10.1083/jcb.200612023 · Cited by 198
“The transcription factor hypoxia-inducible factor-1 (Hif-1) has emerged as the central regulator of hypoxic gene expression (Bunn and Poyton, 1996; Kaelin, 2002; Giaccia et al., 2003; Semenza, 2003; Liu and Simon, 2004).”
BackgroundSelf-citationHypoxic Reactive Oxygen Species Regulate the Integrated Stress Response and Cell Survival
Liu, L., Wise, D. R., Diehl, J. A., & Simon, M. C. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.m805056200 · Cited by 206
CCL2 Blockade Augments Cancer Immunotherapy
Fridlender, Z. G., Buchlis, G., Kapoor, V., Cheng, G., Sun, J., Singhal, S., Crisanti, M. C., Wang, L.-C. S., Heitjan, D., Snyder, L. A., et al. (2010) · Cancer Research · doi:10.1158/0008-5472.can-09-2326 · Cited by 193
The Role of Vitamin D in Cancer Prevention and Treatment
Krishnan, A. V., Trump, D. L., Johnson, C. S., & Feldman, D. (2010) · Endocrinology and Metabolism Clinics of North America · doi:10.1016/j.ecl.2010.02.011 · Cited by 194
Mechanisms of Disease: Cancer stem cells--targeting the evil twin
Trumpp, A., & Wiestler, O. D. (2008) · Nature Clinical Practice Oncology · doi:10.1038/ncponc1110 · Cited by 199
Humphrey, J. S., Price, K., Gupta, E., Baxter, A., Bird, J., Sonnichsen, D., & Naglich, J. (2003) · Chemoradiation in Cancer Therapy · doi:10.1007/978-1-59259-325-5_21 · Cited by 193
García-Maceira, P., & Mateo, J. (2009) · Oncogene · doi:10.1038/onc.2008.398 · Cited by 185
“Given that HIF-1-mediated VEGF expression plays a pivotal role for tumour angiogenesis (Ferrara, 2004), factors that modulate HIF-1 activity are potential targets for anticancer therapy (Giaccia et al., 2003; Semenza, 2003).”
BackgroundInnate Immunity and Angiogenesis
Frantz, S., Vincent, K. A., Feron, O., & Kelly, R. A. (2005) · Circulation Research · doi:10.1161/01.res.0000153188.68898.ac · Cited by 185
MIZUI, Y., SAKAI, T., IWATA, M., UENAKA, T., OKAMOTO, K., SHIMIZU, H., YAMORI, T., YOSHIMATSU, K., & ASADA, M. (2004) · The Journal of Antibiotics · doi:10.7164/antibiotics.57.188 · Cited by 185
Innate immunological pathways in COVID-19 pathogenesis
Paludan, S. R., & Mogensen, T. H. (2022) · Science Immunology · doi:10.1126/sciimmunol.abm5505 · Cited by 169
“In the case of HIF1, hypoxia leads to inhibition of the activity of the prolyl-hydroxylases, which normally hydroxylate HIF1 to link it to the proteasomal pathway, hence allowing accumulation of the transcription factor (69).”
BackgroundGenetic evidence for a tumor suppressor role of HIF-2α
Acker, T., Diez-Juan, A., Aragones, J., Tjwa, M., Brusselmans, K., Moons, L., Fukumura, D., Moreno-Murciano, M. P., Herbert, J.-M., Burger, A., et al. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.07.003 · Cited by 184
Rapisarda, A., Zalek, J., Hollingshead, M., Braunschweig, T., Uranchimeg, B., Bonomi, C. A., Borgel, S. D., Carter, J. P., Hewitt, S. M., Shoemaker, R. H., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-2116 · Cited by 187
“Over the last several years, hypoxia-inducible factor 1 (HIF-1) has emerged as an attractive target for cancer therapy (1, 2).”
BackgroundRedox regulation of the hypoxia-inducible factor
Pouysségur, J., & Mechta-Grigoriou, F. (2006) · Biological Chemistry · doi:10.1515/bc.2006.167 · Cited by 186
“More than 70 genes controlling angiogenesis, erythropoiesis, energy metabolism, cell survival and tumor spreading are targeted by the HIF transcription factor (for reviews, see Semenza, 1999; Giaccia et al., 2003; Pugh and Ratcliffe, 2003a).”
BackgroundMiranda, E., Nordgren, I. K., Male, A. L., Lawrence, C. E., Hoakwie, F., Cuda, F., Court, W., Fox, K. R., Townsend, P. A., Packham, G. K., et al. (2013) · Journal of the American Chemical Society · doi:10.1021/ja402993u · Cited by 185
The hypoxic microenvironment of the skin contributes to Akt-mediated melanocyte transformation
Bedogni, B., Welford, S. M., Cassarino, D. S., Nickoloff, B. J., Giaccia, A. J., & Powell, M. B. (2005) · Cancer Cell · doi:10.1016/j.ccr.2005.11.005 · Cited by 179
“HIF1a plays a major role in the cellular response to hypoxia ( Giaccia et al., 2003 ).”
BackgroundSelf-citationNoman, M. Z., Buart, S., Van Pelt, J., Richon, C., Hasmim, M., Leleu, N., Suchorska, W. M., Jalil, A., Lecluse, Y., El Hage, F., et al. (2009) · The Journal of Immunology · doi:10.4049/jimmunol.0800854 · Cited by 183
“Although the resistance of hypoxic cells to killing and the aggressiveness of highly hypoxic tumors are, in part, due to the overexpression of HIF-1 (14, 15), the consequences of HIF-1 induction on specific lysis of human tumor cells by CTL remain unknown.”
Niu, G., Briggs, J., Deng, J., Ma, Y., Lee, H., Kortylewski, M., Kujawski, M., Kay, H., Cress, W. D., Jove, R., et al. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-07-2177 · Cited by 177
“These stimulators of HIF-1a signal through phosphatidylinositol 3-kinase and Akt, leading to an increased rate of HIF-1a protein synthesis (1, 3).”
BackgroundHIF hydroxylation and cellular oxygen sensing
Metzen, E., & Ratcliffe, P. J. (2004) · Biological Chemistry · doi:10.1515/bc.2004.016 · Cited by 172
“Inhibition of HIF might be predicted to suppress tumour angiogenesis and to reverse adaptation of tumour cells to hypoxia (Giaccia et al., 2003, and references therein).”
BackgroundChemistry and biology of wortmannin
Wipf, P., & Halter, R. J. (2005) · Organic & Biomolecular Chemistry · doi:10.1039/b504418a · Cited by 170
Overexpression of hypoxia-inducible factor and metabolic pathways: possible targets of cancer
Singh, D., Arora, R., Kaur, P., Singh, B., Mannan, R., & Arora, S. (2017) · Cell & Bioscience · doi:10.1186/s13578-017-0190-2 · Cited by 166
Inhibiting Hypoxia-Inducible Factor 1 for Cancer Therapy
Melillo, G. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-06-0235 · Cited by 166
“but not limited to tumor metabolism, angiogenesis, metastasis, and inflammation, and for its potential role as therapeutic target (4-6).”
BackgroundMonocytes and dendritic cells in a hypoxic environment: Spotlights on chemotaxis and migration
Bosco, M. C., Puppo, M., Blengio, F., Fraone, T., Cappello, P., Giovarelli, M., & Varesio, L. (2008) · Immunobiology · doi:10.1016/j.imbio.2008.07.031 · Cited by 166
“Functional or physical interaction of HIF-1 with various cofactors regulating its expression and activity can be sufficient to drive gene transcription (Semenza, 2001, 2003; Wenger et al., 2005; Carroll and Ashcroft, 2006; Sowter et al., 2003; Giaccia et al., 2003).”
BackgroundThe Lethal Phenotype of Cancer: The Molecular Basis of Death Due to Malignancy
Loberg, R. D., Bradley, D. A., Tomlins, S. A., Chinnaiyan, A. M., & Pienta, K. J. (2007) · CA: A Cancer Journal for Clinicians · doi:10.3322/canjclin.57.4.225 · Cited by 161
Inflammation and cancer: Breast cancer as a prototype
Mantovani, A., Marchesi, F., Porta, C., Sica, A., & Allavena, P. (2007) · The Breast · doi:10.1016/j.breast.2007.07.013 · Cited by 159
Scarless wound healing: Transitioning from fetal research to regenerative healing
Moore, A. L., Marshall, C. D., Barnes, L. A., Murphy, M. P., Ransom, R. C., & Longaker, M. T. (2018) · Wiley Interdisciplinary Reviews Developmental Biology · doi:10.1002/wdev.309 · Cited by 172
HIF-1: master and commander of the hypoxic world
Mazure, N. M., Brahimi-Horn, M. C., Berta, M., Benizri, E. I., Bilton, R. L., Dayan, F., Ginouvès, A., Berra, E., & Pouysségur, J. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.04.022 · Cited by 181
New anticancer strategies targeting HIF-1
Yeo, E.-J., Chun, Y.-S., & Park, J.-W. (2004) · Biochemical Pharmacology · doi:10.1016/j.bcp.2004.02.040 · Cited by 158
Merighi, S., Benini, A., Mirandola, P., Gessi, S., Varani, K., Simioni, C., Leung, E., Maclennan, S., Baraldi, P. G., & Borea, P. A. (2007) · Molecular Pharmacology · doi:10.1124/mol.106.032920 · Cited by 156
“A growing body of evidence indicates that HIF-1 contributes to tumor progression and metastasis (Giaccia et al., 2003; Semenza, 2003).”
BackgroundAder, I., Brizuela, L., Bouquerel, P., Malavaud, B. A., & Cuvillier, O. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0917 · Cited by 164
“3, 4). Hundreds of human genes are influenced by HIF-1, and more than 70 of these have been recognized as direct targets (3, 4 ). HIF-1–regulated gene transcription under hypoxia contributes to angiogenesis, metabolic adaptation, resistance to apoptosis, invasion, and metastasis, leading toward a surviving phenotype w…”
BackgroundWan, X., Shen, N., Mendoza, A., Khanna, C., & Helman, L. J. (2006) · Neoplasia · doi:10.1593/neo.05820 · Cited by 164
“Effects of CCI-779 on the Dysregulation of Hif-1a and VEGF In Vivo Hif-1a is a transcription factor that was originally found to be activated in cells in response to hypoxia and is considered an attractive target for cancer therapy because of its pivotal role in cancer development by activating the transcription of ge…”
BackgroundChau, N., Rogers, P., Aherne, W., Carroll, V. A., Collins, I., McDonald, E., Workman, P., & Ashcroft, M. A. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-4453 · Cited by 164
“HIF-1a is overexpressed in many human cancers (15).”
BackgroundVengellur, A., & LaPres, J. J. (2004) · Toxicological Sciences · doi:10.1093/toxsci/kfh278 · Cited by 164
“Hypoxia is defined as a state when oxygen tension drops below normal limits and it plays a central role in development and several pathological conditions including stroke, cardiovascular disease, and tumorigenesis (Giaccia et al., 2003).”
Molecular oxygen as a signaling component in plant development
Weits, D. A., van Dongen, J. T., & Licausi, F. (2020) · New Phytologist · doi:10.1111/nph.16424 · Cited by 145
“As mentioned for tumour cells, the hypoxia-inducible factors HIF-1 and HIF-2 are essential for the tissue to cope with hypoxia and to maintain stem cell fate (Giaccia et al., 2003; Semenza, 2007; Pietras et al., 2009; Ito & Suda, 2014).”
BackgroundThe Tumor Microenvironment in Non–Small-Cell Lung Cancer
Graves, E. E., Maity, A. M., & Le, Q. (2010) · Seminars in Radiation Oncology · doi:10.1016/j.semradonc.2010.01.003 · Cited by 157
Common Molecular Mechanisms of Mammary Gland Development and Breast Cancer
Lundgren, K., Holm, C., & Landberg, G. (2007) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-007-7390-6 · Cited by 157
Metadata
- Authors
- Giaccia, A., Siim, B. G., & Johnson, R. S.
- Affiliations
- Stanford Medicine (US)
- University of Auckland (NZ)
- University of California San Diego (US)
- Corresponding author
- Johnson, Randall S.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2003-10-01
- Volume
- 2
- Issue
- 10
- Pages
- 803-811
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W2075880922
- Cited by
- 631
- References
- 116
- Citations by year
- 2026: 9 · 2025: 14 · 2024: 10 · 2023: 21 · 2022: 26 · 2021: 19 · 2020: 30 · 2019: 14 · 2018: 26 · 2017: 16 · 2016: 20 · 2015: 20 · 2014: 27 · 2013: 30 · 2012: 29
- FWCI
- 3.55
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer, Hypoxia, and Metabolism
- Health Sciences › Medicine › Hematology › Erythropoietin and Anemia Treatment
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Angiogenesis and VEGF in Cancer
- Keywords
- HIF-1, hypoxia-inducible factor, hypoxia, therapeutic target, oxygen sensing, transcriptional regulation, cancer, heart disease, stroke, therapeutic targeting
- MeSH terms
- Animals, Cardiovascular Diseases, DNA-Binding Proteins, Gene Expression Regulation, Humans, Neoplasms, Nuclear Proteins, Oxygen, Transcription Factors, Drug Design, Hypoxia-Inducible Factor 1, Hypoxia-Inducible Factor 1, alpha Subunit
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.